金威医疗(08143) - 2023 Q1 - 季度财报

Cover and Summary Performance Summary For the three months ended June 30, 2022, the Group's revenue grew by 5.92% to HKD 14.06 million, gross margin increased to 83.7%, and loss attributable to owners significantly narrowed to HKD 3.95 million Performance Highlights (HKD) | Indicator | For the Three Months Ended June 30, 2022 | For the Three Months Ended June 30, 2021 | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Revenue | 14,058,000 | 13,272,000 | +5.92% | | Gross Profit Margin | 83.7% | 82.08% | +1.62 percentage points | | Loss Attributable to Owners of the Company | 3,954,000 | 8,740,000 | Loss narrowed | | Dividend | Not declared | Nil | - | Unaudited Condensed Consolidated Financial Statements Consolidated Statement of Profit or Loss and Other Comprehensive Income This quarter, revenue reached HKD 14.06 million with gross profit of HKD 11.77 million, and operating loss narrowed to HKD 2.96 million due to reduced expenses, resulting in a loss attributable to owners of HKD 3.95 million Consolidated Statement of Profit or Loss and Other Comprehensive Income (HKD thousands) | Item | For the Three Months Ended June 30, 2022 | For the Three Months Ended June 30, 2021 | | :--- | :--- | :--- | | Revenue | 14,058 | 13,272 | | Gross Profit | 11,766 | 10,894 | | Selling and Distribution Expenses | (1,817) | (5,463) | | Administrative Expenses | (13,215) | (16,535) | | Loss from Operations | (2,955) | (9,997) | | Loss for the Period | (4,355) | (10,599) | | Loss Attributable to Owners of the Company | (3,954) | (8,740) | | Basic Loss Per Share (HK cents) | (0.140) | (0.310) | Consolidated Statement of Changes in Equity Total equity attributable to owners of the Company decreased from HKD 34.61 million to HKD 21.20 million for the three months ended June 30, 2022, primarily due to the total comprehensive loss incurred - As of June 30, 2022, total equity attributable to owners of the Company was HKD 21.20 million, a decrease from HKD 34.61 million as of April 1, 2022, primarily due to the total comprehensive loss recorded during the period[79] Notes to the Financial Statements This section details the company's information, financial statement preparation basis, key accounting policies, and provides explanations for revenue, taxation, loss per share, and dividends Company Information, Basis of Preparation and Accounting Policies The Company, an investment holding entity registered in the Cayman Islands, primarily operates integrated hospital services in China, with financial statements prepared in HKD under HKFRS and consistent accounting policies - The Company is an investment holding company, with its subsidiaries primarily providing integrated hospital services in China[81] - The financial statements are prepared in accordance with Hong Kong Financial Reporting Standards, with accounting policies consistent with those adopted in the 2021/2022 financial statements[82] Revenue and Taxation All HKD 14.06 million in revenue this quarter came from integrated hospital services, with other income of HKD 0.31 million, and profits in China are subject to a 25% corporate income tax Revenue and Other Income (HKD thousands) | Revenue and Other Income | For the Three Months Ended June 30, 2022 | For the Three Months Ended June 30, 2021 | | :--- | :--- | :--- | | Provision of Integrated Hospital Services | 14,058 | 13,272 | | Total Other Income | 311 | 1,107 | - The Company has made a provision for corporate income tax at approximately 25% for profits generated from providing integrated hospital services in China[86] Loss Per Share and Dividends Basic and diluted loss per share improved to HKD 0.140 cents this quarter from HKD 0.310 cents last year, and the Board does not recommend any dividends Loss Per Share (HKD thousands, HK cents) | Item | For the Three Months Ended June 30, 2022 | For the Three Months Ended June 30, 2021 | | :--- | :--- | :--- | | Loss Attributable to Owners of the Company | (3,954) | (8,740) | | Weighted Average Number of Ordinary Shares in Issue | 2,818,249,944 | 2,818,249,944 | | Basic Loss Per Share (HK cents) | (0.140) | (0.310) | - The Directors do not recommend the payment of a dividend for the three months ended June 30, 2022[91] Management Discussion and Analysis Financial Review Revenue from integrated hospital services grew by 5.92% despite fewer hospitals, while selling and administrative expenses significantly decreased due to a hospital disposal, leading to a narrowed loss attributable to owners - Revenue from one integrated hospital was approximately HKD 14.06 million, an increase of approximately 5.92% compared to HKD 13.27 million from two hospitals in the same period last year[93] - The decrease in selling and distribution expenses and administrative expenses was primarily due to the disposal of Putian Edinburgh Friendly Hospital, decreasing by 66.73% and 20.07% year-on-year respectively[94] - Loss attributable to owners of the Company narrowed from HKD 8.74 million in the same period last year to HKD 3.95 million in the current period[95] Business Review and Outlook The Group operates one integrated hospital in Beijing and plans to shift its strategic focus from disease treatment to prevention, exploring new opportunities in the big health industry and seeking partnerships to enhance market position - The Group will strategically allocate resources to develop disease treatment and management, and explore new potential opportunities related to disease prevention, including upstream and downstream big health industries[98] - Management plans to allocate more resources to support the exploration of new opportunities, including potential collaborations with various business partners or market participants in the healthcare industry[100] Significant Matters and Litigation The Group had no significant acquisitions or disposals this quarter, but an indirect subsidiary faces a lawsuit demanding termination of a cooperation agreement, refund of RMB 12.13 million, and breach of contract compensation - For the three months ended June 30, 2022, the Group had no significant acquisitions or disposals of subsidiaries, associates, or joint ventures[101] - Indirect subsidiary Edinburgh Hospital Management is facing a civil lawsuit from China Merchants, demanding termination of the cooperation agreement, refund of approximately RMB 12.13 million in funds, and payment of related compensation[102] Other Disclosures Directors' and Major Shareholders' Interests in Shares As of June 30, 2022, Director Mr. Wu Zhilong held approximately 58.22% of the Company's interests, with Star Ocean Global Limited holding 56.13% and New Hope International (Hong Kong) Co., Limited holding 12.18% Directors' Interests in Shares | Director's Name | Nature of Interest | Number of Shares | Approximate Percentage of Total Issued Shares | | :--- | :--- | :--- | :--- | | Mr. Wu Zhilong | Personal Interest | 59,000,000 | 2.09% | | | Corporate Interest | 1,581,959,460 | 56.13% | Major Shareholders' Interests in Shares | Name of Major Shareholder | Number of Shares | Capacity | Approximate Percentage of Total Issued Shares | | :--- | :--- | :--- | :--- | | Star Ocean Global Limited | 1,581,959,460 | Beneficial Owner | 56.13% | | New Hope International (Hong Kong) Co., Limited | 343,217,539 | Beneficial Owner | 12.18% | Share Options, Share Repurchases, and Competing Interests The Company's share option scheme expired in August 2021 with no activity, no share repurchases occurred this quarter, and directors confirmed no competing interests - The share option scheme expired on August 10, 2021, and no share options remained unexercised as of the end of the reporting period[123] - For the three months ended June 30, 2022, neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed securities[125] - As of June 30, 2022, none of the Directors or their respective associates held any business that competes or is likely to compete, directly or indirectly, with the Group's business[126] Corporate Governance During the reporting period, the Company complied with GEM Listing Rules' corporate governance code, having established Remuneration, Nomination, and Audit Committees, all with independent non-executive director majorities, and the Audit Committee reviewed the unaudited results - For the three months ended June 30, 2022, the Company complied with the code provisions of the Corporate Governance Code set out in Appendix 15 to the GEM Listing Rules[130] - The Company has established a Remuneration Committee, Nomination and Corporate Governance Committee, and Audit Committee, with their compositions meeting corporate governance requirements[131][133][134] - The Group's unaudited condensed consolidated results have been reviewed by the Audit Committee[136]